Chardan raised the firm’s price target on Arrowhead (ARWR) to $80 from $60 and keeps a Buy rating on the shares. The company reported “encouraging” initial interim data from the Phase I/IIa trials for its two siRNA obesity candidates, ARO-INHBE and ARO-ALK7, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead announces offerings of convertible senior notes and common stock
- Arrowhead Reports Promising Interim Data for Obesity RNAi Trials
- Clear Street keeps Buy on Wave Life Sciences after Arrowhead data
- H.C. Wainwright says initial Phase 1/2a data de-risk Arrowhead obesity franchise
- Arrowhead announces interim results from trials of ARO-INHBE, ARO-ALK7